Introduction
Oestradiol treatment of ovariectomized rats increases the prostaglandin F2aX synthesizing capacity of the uterus in vitro by increasing the amount of prostaglandin synthetase present (Ham, Cirillo, Zanetti & Kuehl, 1975) . Oestradiol treatment of ovariectomized guinea-pigs produces similar results (Naylor & Poyser, 1975) and the action of the oestradiol is not affected by the simultaneous administration of progesterone. During the oestrous cycle of the guinea-pig, the prostaglandin F2a synthesizing capacity of the uterus increases towards the end of the cycle (Poyser, 1972) and prostaglandin F2a levels in the uterine venous plasma rise (Blatchley, Donovan, Horton & Poyser, 1972; Earthy, Bishop & Flack, 1975) . Oestradiol output from the ovary increases during this period (Joshi, Watson & Labhsetwar, 1973; Blatchley, Maule, Walker & Poyser, 1975) , so it is possible that oestradiol is the physiological stimulus for increased synthesis and release of prostaglandin F2a from the uterus.
There is much clinical interest at present in drugs which inhibit prostaglandin synthesis. The nonsteroidal, anti-inflammatory drugs inhibit prostaglandin synthetase (Vane, 1971) and thereby prevent the conversion of the precursor fatty acids into prostaglandins. Prostaglandin synthetase is apparently inactivated during the formation of prostaglandins (Lands, LeTellier & Vanderhoek, 1973) , so the continual synthesis of new enzyme would appear a critical factor in determining the amounts of prostaglandins formed by a tissue. If the levels of prostaglandin synthetase in certain tissues are under hormonal control, drugs which inhibit the action and/or release of the hormone should maintain low levels of enzyme in the tissue and thereby reduce the prostaglandin synthesizing capacity of that tissue. Such drugs may be of clinical importance in inhibiting prostaglandin synthesis.
In this study, we have tested the effect of the antioestrogen, tamoxifen (Harper & Walpole, 1967) on the prostaglandin synthesizing capacity, in vitro, of the pseudopregnant rat uterus. Tamoxifen is an antioestrogenic drug in the rat, antagonizing the effects of circulating oestrogen at the tissue level (Harper & Walpole, 1967) . It has also been shown to reduce the output of oestradiol from the rat ovary, either by directly inhibiting the ovarian synthesis of oestradiol, or indirectly by blocking follicle stimulating hormone release from the pituitary (Watson, Anderson, Alum, O'Grady & Heald, 1975) . Plasma oestradiol levels in the pseudopregnant rat show a small rise up to day 4 (though the peak level may be late on day 3), fall to a lower level which is maintained up to about day 9 or 10, then increase rapidly over the next 3 days (Welschen, Osman, Dullaart, De Greef, Uilenbroek & De Jong, 1975) . Initially, we had to study how much prostaglandin was produced normally by the rat uterus on each day of pseudopregnancy. This is of interest also since prostaglandin F2a released from the rat uterus may be the endogenous substance which terminates pseudopregnancy in the rat (Saksena, Watson, Lau & Shaikh, 1974; Weems, Pexton, Butcher & Inskeep, 1975; Castracane & Shaikh, 1976 (Poyser, 1972 (Mitchell, Poyser & Wilson, 1976 (Poyser & Horton, 1975) , though the plagma usually had to be diluted 10 times with distilled water before assay. The values obtained were in the expected range (Welschen et al., 1975) , though marginally lower.
Effect of tamoxifen on prostaglandin production by thepseudopregnant rat uterus in vitro This study was performed following the results obtained from the first experiment, and in light of the reported finding that tamoxifen administered on day 2 to pregnant rats inhibits the increased output of oestradiol from the ovary which normally takes place on days 3 and 4 (Watson et al., 1975) . Five rats were injected subcutaneously at 11 h 00 min on day 2 of pseudopregnancy with 0.05 mg tamoxifen (approx. 0.25 mg/kg). The drug was provided absorbed on to mannitol (1%) and was dissolved in 0.5% aqueous Tween 80 so that 0.5 ml contained 0.05 mg tamoxifen. Five control rats were injected with 0.5 ml aqueous Tween 80 at the same time on day 2. All rats were killed on the morning of day 5. Peripheral plasma levels of progesterone and prostaglandin production by uterine incubates were measured by radioimmunoassay, as in the first experiment.
Identification ofprostaglandins
To facilitate the handling and identification of prostaglandins, samples from several days were pooled together, namely days 2, 4 and 5 (from the first experiment), days 7 and 9, half the samples from each of days 10, 11 and 12, and the samples from the second experiment. This gave 5 pooled samples. (The specific and more detailed analysis of the remaining samples forms an addendum to this paper). Table 1 for number of animals used per day); s.e. means represent 'between rat' variations.
Each pooled sample was evaporated to dryness and the residue dissolved in 20 ml 67% ethanol. This solution was washed twice with 20 ml petroleum ether (b.p. 600 to 800C), and then evaporated to dryness.
The extract was further purified by silicic acid column chromatography performed as described by Blatchley et al. (1972) .
Prostaglandins present in the 'F' fraction from the column were converted into the corresponding methyl ester trimethylsilyl ethers (Me-TMS). (Blatchley et al., 1972) . The Me-TMS derivatives of authentic prostaglandins Fla and F2a were prepared for comparative purposes when the extracts were analysed by combined gas chromatography and mass spectrometry (GC-MS).
Prostaglandins present in the 'E' fraction from the column were converted to the methyl esters by reacting with diazomethane for 15 minutes. The nbutyloximes were then prepared by reacting the methyl esters with O-n-butylhydroxylamine hydrochloride (5 mg/ml in dry pyridine) for 90 min at 600C. Finally the trimethylsilyl ethers were prepared by reacting the methyl n-butyloximes with 20 1il N,Nbis(trimethylsilyl)-trifluoroacetamide (BSTFA) at 60°C for 15 minutes. The same derivatives of prostaglandin E2, E1, D2 and 13,14,dihydro-15,ketoprostaglandin F2a were also prepared for comparative purposes when the extracted samples were analysed by GC-MS.
Results

Prostaglandin production by the pseudopregnant rat uterus in vitro
The results are shown in Figure 1 and the amounts of prostaglandins produced are expressed as ng prostaglandin per 100 mg tissue. Levels of prostaglandins F and D were significantly higher on day 2 than on day 3 (P<0.01). Levels rose significantly on day 4 (P < 0.01) and again on day 5 (P < 0.05), to reach the highest value seen on any day of pseudopregnancy. Levels fell significantly on day 6 (P <0.01), rose significantly on day 7 (P <0.05), fell significantly on day 8 (P< 0.01), and rose significantly again on day 9 (P<0.01) to remain relatively stable, with small fluctuations, up to the end of pseudopregnancy.
Prostaglandin E levels again showed a peak at day 5, but did not show the same fluctuations from day to day as did the levels of prostaglandins F and D. The levels of prostaglandin E were similar on days 2 and 3, rose significantly on day 4 (P < 0.05) and again on day T=tamoxifen-treated (5 rats).
OH OH 5 (P<0.01). From this peak, prostaglandin E levels gradually fell to reach low levels between days 10 and 13. A comparison of the ratios of the levels of prostaglandins F and D to the level of prostaglandin E is interesting. This ratio steadily decreases from days 2 to 6, possibly indicating that prostaglandin E production is stimulated more than that of F and D. The ratio then shows a sudden rise on day 7, since prostaglandin F and D levels increase on that day while prostaglandin E levels fall. The ratio falls slightly on days 8 and 9 before rising to its highest values between days 10 and 13. This high ratio is due to the very low level of prostaglandin E production rather than to a high level of production of F and D.
Plasma progesterone levels (Table 1) increase rapidly during the first 3 days of pseudopregnancy reaching high levels by day 4 or 5. The levels then show small fluctuations up to day 9, after which they decline to much lower levels by day 13. It may be that the increase in production of prostaglandins F and D from day 8 to 9, and the relatively higher production of prostaglandins F and D in comparison to E from days 10 to 13 may be connected with this decline. It is clear that the much higher production of prostaglandins F and D on day 5 is not connected with any decline in progesterone levels.
Effect of tamoxifen on prostaglandin production by the pseudopregnant rat uterus in vitro
The results are shown in Figure 2 . The pretreatment of rats on day 2 with tamoxifen significantly decreased the in vitro production of prostaglandins by the day 5 pseudopregnant rat uterus. However, the production Figure 3 Structures of 6-keto prostaglandin F, af (I) and 6(9)-oxy-1 1,1 5-dihydroxyprosta-7,1 3-dienoic acid (11).
of prostaglandin E was apparently affected more since the ratio of prostaglandins F and D to E was 2.0 in the control animals, but increased to 3.5 in the drugtreated animals. Peripheral plasma progesterone levels were high in both groups, as expected, and did not differ.
Identification ofprostaglandins 'F' fraction. The predominant prostaglandin present was FM in all samples studied. Much smaller quantities (1 to 5%) of Fia were also detectable. 'E'fraction. Prostaglandin E2 was identified as being present in all samples. Smaller quantities of prostaglandin D2 were also present in each sample. Neither prostaglandin El nor 13,14-dihydro-1 5-ketoprostaglandin F2a were detected. The major product present in each sample was 6-keto-prostaglandin Fla (Figure 3 ). The identification of this compound by GC-MS in the remaining uterine extracts forms an addendum to this paper. It was estimated to be present in quantities at least 10 to 20 times more than the quantities of prostaglandin E2, and, therefore, was also present in greater quantities than F2a. It was impossible to measure the quantities accurately since the authentic compound was not available.
Also present was another prostaglandin derivative. Its mass spectrum was identical to that of a compound produced by rat stomach homogenates and which has I been identified as 6(9)-oxy-1 1,15-dihydroxyprosta-7,13-dienoic acid (Pace-Asciak and Wolfe, 1971a) (Figure 3) . It was present in quantities less than 6-keto-prostaglandin Fla but probably more than F2M.
An accurate measurement of the amounts again was not possible.
Discussion
It was unexpected that a major prostaglandin produced by rat uterus homogenates would be 6-ketoprostaglandin Fla. The isolation of this prostaglandin from the uterus has not been previously reported. 6-Keto-prostaglandin Fla was produced in amounts at least 5 to 10 times greater than the amounts of F2a the prostaglandin in next abundance. We did not have any authentic 6-keto-prostaglandin Fla to test its cross-reactivity with the FM antibody. Prostaglandin Fla cross-reacts 100%, but the introduction of a 6-keto group may reduce the cross-reactivity. Perhaps of more significance was the finding that 6-ketoprostaglandin Fla is similar in polarity to prostaglandin E2. It was eluted in the 'E' fraction from the silicic acid columns and its retention time of gas chromatography was 1 to 2 min longer than that of prostaglandin E2. This is despite that fact that 6-ketoprostaglandin Fla contains 3 hydroxyl groups while E2 contains only 2 such groups. This probably indicates that the 6-keto group and 9-hydroxyl group interact in some way, resulting in a reduction in polarity of the molecule. This interaction may also reduce the affinity of 6-keto-prostaglandin Fla for the It was also unexpected that 6(9)-oxy-11,15-dihydroxyprosta-7,13-dienoic acid would be produced by rat uterus homogenates, though it is known to 6e produced by the rat stomach (Pace-Asciak & Wolfe, 1971a From the quantitative results, it is seen that prostaglandin production is highest on day 5 of pseudopregnancy. The level measured is the sum of the amount already present in the uterus plus that synthesized during incubation minus the amount metabolized.
13,14-Dihydro-15-keto-prostaglandin (which is similar in polarity to prostaglandin E2) was not detected. It would appear that in this in vitro system, metabolism of prostaglandins is low and we were actually measuring prostaglandin synthesis by the uterus. However, a detailed study of metabolism is merited. Day 5 is the day of implantation in the rat and it is possible, that a high production of prostaglandins on day 5 is connected with this process.
The increase in production of prostaglandins by the uterus on day 5 of pseudopregnancy was significantly inhibited by treating the rats with tamoxifen on day 2. Tamoxifen, at this dose level, inhibits the output of oestradiol from the ovary (Watson et al., 1975) . This would indicate that the increase in prostaglandin production normally occurring from day 3 to day 5 is linked to the increased output of oestradiol from the ovary which occurs late on day 3 and early on day 4. These results also suggest that drugs which inhibit the release and/or action of hormones may be of importance in inhibiting prostaglandin synthesis. In this study, other mechanisms of action of tamoxifen cannot be ruled out. Ham et al. (1975) showed that the treatment of ovariectomized rats with oestradiol stimulated prostaglandin F2 synthesis by the uterus but reduced E2 synthesis. This resulted in an increase in the ratio of prostaglandins F to E. This did not occur in the day 5 uterus in the present study. Synthesis of all prostaglandins was apparently stimulated with prostaglandin E2 synthesis actually being stimulated more, as the ratio of prostaglandins F and D to E decreased. It is difficult to explain this difference in findings except that in this study progesterone levels were high, while in the study of Ham et al. (1975) , the ovariectomized rats were not receiving progesterone supplements.
It was also surprising that prostaglandin production did not increase greatly towards the end of pseudopregnancy when oestradiol levels are high. The ratio of prostaglandin F and D to E did increase, and possibly this is of significance. Uterine levels of pro-staglandin F2a do not increase greatly towards the end of pseudopregnancy, though they are significantly higher around days 9 and 10 (Weems et al., 1976; Castracane & Shaikh, 1976) . Oestrogen does cause the release of prostaglandin F from the uterus of ovariectomized rats though a period of progesterone priming is necessary for the maximum effect to be produced (Castracane & Jordan, 1975) . Whether or not prostaglandin F2a produced by the rat uterus is the factor which terminates pseudopregnancy has still to be proven. Our finding that 6-keto-prostaglandin Fla is the major product formed by rat uterus homogenates, raises the possibility that this compound may be the uterine luteolytic hormone in the rat. Consequently, many of the earlier studies may need to be re-appraised in the light of our present findings. The identification of a compound by gas chromatography and mass spectrometry involves the formation of different chemical derivatives and the interpretation of the mass spectra produced following gas chromatography. It is essential to choose derivatives which identify the nature and position of the functional groups present. Since the extraction and chromatographic procedures described in the preceding paper are directed towards isolating prostaglandins, it was highly probable that the new compound isolated had a prostaglandin-like structure. The determination of the structure of this compound is the subject of this addendum.
Methods
Ethyl acetate extracts of pseudopregnant rat uteri were pooled to produce several larger samples consisting of 4 or 5 individual samples. Each pooled sample was evaporated to dryness, the residue dissolved in 67% ethanol and washed with petroleum ether (b.p. 600 to 800C). The ethanol solution was evaporated to dryness and the residue further purified by column chromatography, as described in the preceding paper.
The 'E' fraction from each column was subjected to derivatization for analysis by gas chromatographymass spectrometry. Methyl ester formation, nbutyloximation of the keto groups, and trimethylsilyl ether formation were performed as described in the preceding paper. Ethyl esters were prepared using diazoethane, and methyloximes formed with 0-methylhydroxylamine hydrochloride (5 mg/ml in dry pyridine). Cyclic n-butylboronates were formed by reacting the esterified compound with n-butylboronic acid (5 mg/ml in 2,2-dimethoxypropane) for 60 min at 600C.
The keto group in the unknown compound was reduced also with sodium borohydride in ethanol at room temperature for 30 minutes. After the addition of water and acidification to pH 4.5 with 1 N HCI, the reduced compound was extracted with ethyl acetate. It was then converted into the methyl or ethyl ester, trimethylsilyl ether. Seven derivatives of the unknown compound were prepared.
Analyticalprocedure
The derivatives were analysed on an LKB 9000 gas chromatograph-mass spectrometer. The glass column, 3 m x 3 mm, was packed with 3% OV 1 on Supelcoport. The helium gas flow was 35 miminute. The column temperature was 2450C, or 2480C when oximes were analysed. A mixture of straight chain fatty acid methyl esters (consisting of 16 to 24 carbons) was run before each sample in order to calculate its carbon value (C value). 
Results and Discussion
(1) Methyl ester, O-n-butyloxime, trimethylsilyl ether (Me-BuO-TMS) Two oxime isomers were obtained which separated on gas chromatography (C values=26.5 and 26.8). The mass spectrum of the second isomer is shown in Figure 4 . identical fragmentation as in the Me-BuB-TMS derivative. The evidence accumulated from these 5 derivatives indicates that the compound isolated consists of a prostaglandin Fia structure with a keto group attached to the a-chain. The fragmentation patterns of the derivatives prepared so far give little indication where the keto group is actually located on the a-chain. It was decided, therefore, to reduce the keto group to a hydroxyl group since carbon-carbon bonds split a to a carbon-oxygen bond (as in the loss of 71 and 173 around the carbon-oxygen bond at position 15; Figure 4 ). The fragmentation pattern of the a-chain should, establish the position of the keto groups.
(6) Methyl ester, trimethylsilyl ether (Me-TMS) of the reduced compound The reduction of the keto group produces two isomers.
Our experience of 15(R) and 15(S) prostaglandin F2a has shown that these two isomers do not separate on gas chromatography. It was no surprise, therefore, that the reduced form of the compound under study produced only one gas chromatographic peak (C value= 25.0). Its mass spectrum is shown in Figure 5 and the following points are noted: (i) The mol. wt. is 674, which is consistent with the compound being prostaglandin Fia containing one extra hydroxyl group.
(ii) A major peak occurs at m/e 217. As shown in the figure, this most probably arises from a split of the bond between carbons 6 and 7, which is a to the carbon-oxygen bond. (iii) The base peak at m/e 191 is due to the loss of the a chain, the two derivatized hydroxyl groups from the cyclopentane ring and the loss of the 5 terminal carbons from the o-chain. (iv) Since peak m/e 191 is formed preferentially, peaks at m/e 173 and 199 are correspondingly small. (v) There are several significant peaks indicating the loss of derivatized hydroxyl groups (90) and the 5 terminal carbons (71). The peak at m/e 584 (M-90) corresponds to the mol. wt. of prostaglandin F2a (Me-TMS) and the mass spectrum between m/e 300 and 600 is remarkably similar to that of prostaglandin F2a
(not Fia since one would have to add 2 protons to compensate for the loss of one derivatized hydroxyl group) (see Poyser, 1972 , for a mass spectrum of prostaglandin F2a-Me-TMS).
(7) Ethyl ester, trimethylsilyl ether (Et-TMS) of the reduced compound Only one peak was produced on gas chromatography (C value= 25.2). The mass spectrum of the Et-TMS of the reduced compound is shown in Figure 5 : (i) The mol. wt. is 688, 14 mass units higher than the Me-TMS derivative, as expected. (ii) The base peak is at m/e 191, as expected also, since the production of this fragment involves loss of the a-chain and is, therefore, not affected by the ester derivative. (iii) If the derivatized hydroxyl group is located at position 6, one would now expect the m/e 217 peak present in the Me-TMS derivative to move to m/e 231 in the Et-TMS derivative. A comparison of the mass spectra shows this to be the case, proving conclusively that the hydroxyl group (and, therefore, the original keto group) is located on the carbon at position 6.
Conclusion
The evidence obtained from this study clearly indicates that the new compound isolated from the pseudopregnant rat uterus is 6-keto-prostaglandin Fla. This conclusion does make the assumption that both hydroxyl groups on the cyclopentane ring are in the a positions, and that the double bond in the cchain is in the 13,14 position. However, naturallyoccurring prostaglandins of the F series do have this configuration so hopefully these assumptions are justified. Absolute identification must await the chemical synthesis of the authentic compound and a comparison being made of the mass spectra of the naturally-occurring and synthetic material. Finally, whilst this study was in progress a short report was published showing that 6-ketoprostaglandin Fla is also formed by homogenates of rat stomach (Pace-Asciak, 1976) .
